Press Releases

Press Releases

May 11, 2021
Quarterly Records: AVISE ® CTD Volumes, Ordering Healthcare Providers and Adopters SAN DIEGO , May 11, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2021 .
May 3, 2021
SAN DIEGO , May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate and timely
April 27, 2021
SAN DIEGO , April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021 . Ron Rocca , Exagen’s President and Chief Executive
March 22, 2021
SAN DIEGO , March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share.
March 22, 2021
SAN DIEGO , March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
March 16, 2021
Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters SAN DIEGO , March 16, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2020 .
Displaying 1 - 10 of 16